A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis | Zendy

Yuichi Ohashi | Zendy; Nobuyuki Ebihara | Zendy; Hiroshi Fujishima | Zendy; Atsuki Fukushima | Zendy; Naoki Kumagai | Zendy; Yayoi Nakagawa | Zendy; Kenichi Namba | Zendy; Shigeki Okamoto | Zendy; Jun Shoji | Zendy; Etsuko Takamura | Zendy; Kunihiko Hayashi | Zendy

Open Access

A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis

Author(s) -

Yuichi Ohashi,

Nobuyuki Ebihara,

Hiroshi Fujishima,

Atsuki Fukushima,

Naoki Kumagai,

Yayoi Nakagawa,

Kenichi Namba,

Shigeki Okamoto,

Jun Shoji,

Etsuko Takamura,

Kunihiko Hayashi

Publication year - 2010

Publication title -

journal of ocular pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.727

H-Index - 61

eISSN - 1557-7732

pISSN - 1080-7683

DOI - 10.1089/jop.2009.0087

Subject(s) - medicine , tacrolimus , placebo , itching , adverse effect , visual analogue scale , clinical endpoint , anesthesia , randomized controlled trial , allergic conjunctivitis , photophobia , surgery , dermatology , allergy , transplantation , immunology , pathology , alternative medicine

To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research